CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung
Authors:
- Seung-Hun ShinSSSeung-Hun Shin
- Seon-Hee YimSYSeon-Hee Yim
- Kyo Young LeeKLKyo Young Lee
- Hyun-Mi KangHKHyun-Mi Kang
- Tae-Min KimTKTae-Min Kim
- Yeun-Jun ChungYCYeun-Jun Chung
- 1 July 2007
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 57 (1) , 46-53
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Colocalization of the Tetraspanins, CO-029 and CD151, with Integrins in Human Pancreatic Adenocarcinoma: Impact on Cell MotilityClinical Cancer Research, 2005
- Molecular oncology — perspectives in lung cancerLung Cancer, 2004
- A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cellsExperimental & Molecular Medicine, 2003
- Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancerOncogene, 2003
- Regulatory role of tetraspanin CD9 in tumor–endothelial cell interaction during transendothelial invasion of melanoma cellsBlood, 2001
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- A novel molecular staging protocol for non-small cell lung cancerOncogene, 1999
- Secretory lysosomes — a special mechanism of regulated secretion in haemopoietic cellsTrends in Cell Biology, 1996
- Intracellular trafficking of lysosomal membrane proteinsBioEssays, 1996
- The ins and outs of the transmembrane 4 superfamilyImmunology Today, 1994